用ribozyme抑制增殖细胞核抗原的表达对HeLa细胞增殖的影响

增殖细胞核抗的（ＰＣＮＡ）是ＤＮＡ聚合酶δ的辅助蛋白,它是细胞染色体ＤＮＡ复制所必需的。人工设计的ｒｉｂｏｚｙｍｅ具有可特异地切割ＰＣＮＡｍＲＮＡ的性质,将此ｒｉｂｏｚｙｍｅ的自剪体内表达质粒导入ＨｅＬａ细胞,从细胞决ＲＮＡ中分离相应部分能在体外切割靶ＲＮＡ片段,证明此表达质粒在细胞内能表达出有活性的ｒｉｂｏｚｙｍｅ分子。与对照相比,导入ｒｉｂｏｚｙｍｅ表达质粒的ＨｅＬａ细胞进入Ｓ期的时间从１２ｈ     

DNA损伤诱导的长链非编码RNA-UCA1促进HeLa细胞增殖

尿路上皮癌抗原1 (UCA1)是一种长链非编码RNA,在多种肿瘤内高表达.然而,其在宫颈癌细胞和组织中的表达报告颇不一致,且功能尚未确定.本文探索UCA1在宫颈癌HeLa细胞中的生物学功能.实时定量PCR（qRT-PCR）结果显示,UCA1、p21和p53 mRNA在阿霉素（doxorubicin,DOX）或γ射线照射的HeLa细胞中表达上调|相反,敲减p53表达则可抑制DOX诱导的UCA1上调.表明DNA损伤诱导的UCA1可能与p53有关.转染结合CCK8检测HeLa细胞增殖活力结果显示,与对照比较,过表达UCA1促进HeLa细胞增殖,干扰UCA1表达则减缓细胞增殖.此外,流式细胞术结果显示,过表达UCA1导致阿霉素诱导的凋亡率下降;siRNA抑制UCA1表达后引起细胞G2/M期比例上升,S期下降,且阿霉素诱导的细胞凋亡率上升.上述结果说明,DNA损伤诱导的UCA1可促进HeLa细胞增殖,减少细胞凋亡.然而,是否DNA损伤诱导的UCA1上调依赖p53尚需进一步实验证明.     

siRNA抑制c-myc基因的表达对宫颈癌细胞增殖的影响

目的:利用siRNA(small interference RNA)技术研究c-myc基因的对宫颈癌HeLa细胞增殖的影响.方法:依据Promega公司在网上提供的设计软件,设计针对c-myc基因的siRNA,合成DNA模板,体外转录合成siRNA.通过阳离子聚合物jet-SITM-ENDO将合成的siRNA转染入HeLa细胞,以未转染细胞以及错义序列siRNA-scr转染细胞为对照.用细胞计数法检测siRNA对HeLa细胞增殖的影响.流式细胞法检测细胞周期及蛋白表达的变化,RT-PCR法比较转染前后c-myc mRNA表达水平的变化.结果:细胞计数法结果显示,转染24h后c-myc基因siRNA明显抑制MCF-7细胞增殖,转染48h后,抑制效率稳定.c-myc基因siRNA转染后能有效地抑制HeLa细胞的增殖,阻滞细胞周期于G0/G1期,siRNA转染组c-myc mRNA、蛋白的表达量明显低于空白对照组、错义序列组.结论:体外转录合成的siRNA可有效降低HeLa细胞c-myc基因的表达,抑制细胞增殖.     

siRNA抑制c—myc基因的表达对宫颈癌细胞增殖的影响

目的：利用siRNA（small interference RNA）技术研究C-myc基因的对宫颈癌HeLa细胞增殖的影响。方法：依据Promega公司在网上提供的设计软件,设计针对C-myc基因的siRNA,合成DNA模板,体外转录合成siRNA。通过阳离子聚合物jet—SITM—ENDO将合成的siRNA转染入HeLa细胞,以未转染细胞以及错义序列siRNA—scr转染细胞为对照。用细胞计数法检测siRNA对HeLa细胞增殖的影响。流式细胞法检测细胞周期及蛋白表达的变化,RT—PCR法比较转染前后C-myc mRNA表达水平的变化。结果：细胞计数法结果显示,转染24h后c-myc基因siRNA明显抑制MCF-7细胞增殖,转染48h后,抑制效率稳定。c-myc基因siRNA转染后能有效地抑制HeLa细胞的增殖,阻滞细胞周期于G0／G1期,siRNA转染组c-myc mRNA、蛋白的表达量明显低于空白对照组、错义序列组。结论：体外转录合成的siRNA可有效降低HeLa细胞c-myc基因的表达,抑制细胞增殖。     

丙型肝炎病毒RNA特异性核酶的切割活性研究

针对丙型肝炎病毒RNA(HCV-RNA)的5′非编码区和部分C区的二级结构,设计并合成了四个不同的锤头型核酶(ribozyme A, ribozyme B, ribozyme C₁, ribozyme C₂).首先应用体外切割实验筛选出作用于HCV-RNA起始密码子上游GTA↓位点的核酶RzA有较好的活性.为初步验证核酶RzA在细胞内的切割活性,经脂质体介导,将RzA-RNA与另一携带该核酶靶基因的质粒表达载体pCl-neo-luciferase(载体中荧光素酶基因受核酶靶基因的调控)共转染HepG₂细胞.通过测定荧光素酶基因的表达证实了核酶在细胞内有较好的切割活性.在此实验基础上,把RzA基因克隆至pCl-neo质粒表达载体中,再次经脂质体介导,将重组的表达载体pCl-neo-RzA与携带该核酶靶基因的质粒表达载体pCl-neo-luciferase共转染HepG₂细胞,获得了更好的切割效果.     

鸟氨酸脱羧酶基因反义RNA对肝癌细胞HepG2的影响

目的：探讨鸟氨酸脱羧酶（ornithine decarboxylase,ODC）基因反义RNA对肝癌细胞HepG2的影响。方法：构建ODC反义RNA的真核表达质粒,将此质粒转染HepG2细胞后,RT-PCR和Western印迹法筛选ODC表达抑制的细胞株。以此细胞株为模型,分析ODC反义RNA对细胞生长、细胞周期和对抗癌药物米托蒽醌敏感性的影响。结果：成功构建ODC反义RNA真核表达载体并获得稳定低表达ODC的肝癌细胞株Hr1。与对照细胞相比,ODC低表达引起HepG2细胞生长抑制,72h生长抑制率为31%;流式细胞术检测细胞周期发现,Hr1G1期细胞数（56.2%）显著性高于对照（48.2%）,而S期细胞（25.5%）则显著性低于对照（34.9%）,提示ODC低表达导致G1期阻滞;用米托蒽醌（100μg/L）处理两种细胞后发现,Hr1对药物的敏感性显著性高于对照细胞,处理48h后药物对HepG2和Hr1的抑制率分别是33.4%和60.6%,72h后的抑制率分别是60.8%和83.8%。结论：ODC反义RNA能抑制肝癌HepG2细胞生长,在抗肿瘤治疗中具有潜在的临应用价值。     

人脆性组氨酸三联体（FHIT）基因的克隆及在HeLa细胞中表达的研究

目的：构建人脆性组氨酸三联体（fragile histidine triad gene,fhit）基因与报告基因egfp的双顺反子表达载体及融合表达载体,研究fhit基因过表达对HeLa细胞生长及凋亡的影响。方法：根据已知fhit基因的mRNA序列,RT-PCR得到493bp的cDNA序列,将其构建到pMD18-T中,筛选目的片段插入正确的重组质粒,经限制性内切酶切割,回收目的片段分别插入双顺反子表达载体pIRES2-EGFP和融合表达载体pEGFP-C1的多克隆位点中。再以脂质体介导转染HeLa细胞,G418筛选稳定转染的克隆,分别通过基因组PCR、RT-PCR、免疫细胞化学及TUNEL法在DNA、RNA和蛋白质水平检测其表达情况。结果：转基因细胞基因组PCR获得493bp片段,证明目的基因已整合到细胞基因组中;RT-PCR检测其在RNA水平得到表达;免疫细胞化学及TUNEL法分析表明fhit基因在HeLa细胞内实现了稳定遗传与表达。结论：实验证明fhit基因过表达可有效促进HeLa细胞的凋亡。     

靶向XBP1S的RNA干扰质粒对细胞增殖的影响

目的 构建靶向人XBP1S的siRNA真核表达载体（pSUPER-XBP1S）并观察其对人HeLa细胞和HepG2细胞增殖能力的影响.方法 设计并合成针对XBP1S基因的siRNA,退火成互补双链后克隆至真核表达载体pSUPER构建重组质粒,并将其转染入HeLa细胞和HepG2细胞中.采用RT-PCR检测转染前后XBP1S在HeLa细胞和HepG2细胞中的转录,Western印迹检测转染前后XBP1S蛋白的表达;MTT法、细胞计数检测重组质粒对HeLa细胞和HepG2细胞增殖能力的影响.结果 重组质粒能有效地抑制HeLa细胞和HepG2细胞中XBP1S基因的转录和表达;转染HeLa细胞和HepG2细胞后,细胞增殖抑制率及细胞增殖数与对照组比较,差异有统计学意义（P〈0.05）.结论 成功构建了靶向人XBP1S的siRNA表达载体pSUPER-XBP1S,并且有效的抑制了HeLa细胞和HepG2细胞中XBP1S的转录和表达,有效抑制了细胞的增殖能力.     

蛋白激酶A抑制剂对HeLa细胞S期进程的影响

以同步化的HeLa细胞为实验材料,研究了蛋白激酶A(PKA)抑制剂对HeLa细胞S期进程的影响及其作用的分子机理.通过TdR双阻断法,获得了同步化的S期细胞,3H-TdR掺入实验表明PKA抑制剂typeⅢ(80mg/L)明显提高了S期3H-TdR的掺入水平,提示了PKA在S期进程中起阻抑作用.进一步实验表明,在PKA抑制剂typeⅢ作用下胸苷激酶(TK)活性和PCNA蛋白水平均有所提高,同时明显促进了CyclinA蛋白的表达,并抑制了周期负调因子p21蛋白的水平,但对CDK2表达几乎无影响.结果表明,PKA可通过作用于PCNA和引擎分子CyclinA的水平和通过影响p21的表达负调于S期进程.这可能是PKA负调HeLa细胞S期进程的分子机理之一.     

小环载体介导的siRNA 稳定抑制乙肝病毒的复制和表达

【目的】尝试构建表达小干扰RNA(small interfering RNA,siRNA)的小环载体,并初步鉴定其对乙肝病毒(hepatitis B virus,HBV)复制及其基因表达的抑制作用。【方法】设计并合成靶向HBV S区的siRNA,将其克隆到小环载体pMC.BESPX-MCS2上,测序正确后将重组体pMC-H1-siHBS-U6转化入感受态E.coliZYCY10P3S2T,然后在培养基中加入L-阿拉伯糖,诱导其降解细菌骨架,获取只含有目的基因表达盒的小环RNA干扰载体pmc-H1-siHBS-U6。将小环RNA干扰载体与HBV真核表达质粒pHBV1.3共转染Huh-7细胞,分别在转染后1-7天,ELISA法检测Huh-7细胞上清中的HBsAg、HBeAg,并且通过Real-time RT-PCR法分析干扰RNA对HBV DNA及mRNA的抑制效果。【结果】成功构建了靶向HBV S基因的siRNA小环表达载体pmc-H1-siHBS-U6。该载体能显著抑制Huh-7细胞HBsAg和HBeAg分泌,并且其抑制效果能够维持2-3周时间。Real-time PCR证实HBV的DNA与mRNA水平分别降低了71%和80%,而对照siRNA及空载体则无此作用。【结论】成功构建了靶向HBV的小环RNA干扰载体,并且其能稳定、高效、特异地抑制HBV基因的表达与复制,该研究不仅对探索HBV的基因治疗提供了重要线索,而且为RNA干扰的应用提供了新的运载体系。     

Inhibition of hepatitis B virus by hammerhead ribozyme targeted to the poly(A) signal sequence in cultured cells

The deviant poly(A) signal of hepatitis B virus (HBV) not only controls the formation of the 3' end of all the viral RNA, but is also crucial for HBV replication. Hence, a cis-releasing hammerhead ribozyme (RzA) targeted to the poly(A) signal region of HBV subtype adr was investigated for its antiviral effects. In vitro, RzA cleaved HBV RNA at its target site up to 70%, while the disabled ribozyme (dRzA), which had a one-base mutation in the catalytic site, did not cleave the target RNA at all. When the ribozymes were cotransfected into HepG2 cells with the HBV genome-containing plasmid p3.6II, the wild-type ribozyme RzA could effectively decrease HBV RNA levels and inhibit HBV replication, whereas its disabled form, dRzA, had much weaker effects, indicating that the active catalytic domain of the hammerhead ribozyme could markedly increase the extent of antisense-mediated inhibition. In addition, there was a gradient of effectiveness: the higher the amount of released ribozyme, the more the reduction in target HBV RNA in cells as well as progeny DNA reduction. These results suggest the possibility of the hammerhead ribozyme RzA to be used for the gene therapy of HBV infection.     

细胞周期蛋白D1特异性核酶表达载体的构建及其活性

应用mfold程序对锤头状核酶(ribozyme,Rz)和大鼠细胞周期蛋白(cyclin)D1基因的二级结构进行分析,设计合成锤头状Rz基因,通过RT-PCR扩增获得大鼠细胞周期蛋白D1目的基因,将Rz基因和细胞周期蛋白D1基因分别克隆入载体pGEM-3Zf( )中,体外转录Rz基因和靶基因并进行切割实验;将Rz基因与逆转录病毒载体pLXSN重组得到Rz真核表达载体pLXSN-Rz,将其转染入HSC-T6细胞,G418筛选出阳性细胞克隆,用RT-PCR检测细胞周期蛋白D1基因的表达。结果显示:针对目的基因的832位点设计合成了Rz832,成功获得Rz832基因、细胞周期蛋白D1mRNA的体外转录载体pGEM3Zf-Rz832和pGEM3Zf-cD1,经体外转录出Rz832(105nt)及细胞周期蛋白D1mRNA(1079nt)。体外切割实验证实Rz832能够特异性切割细胞周期蛋白D1mRNA,产生1014nt和65nt的切割产物,切割效率为80%。所构建的pLXSN-Rz832经酶切电泳、PCR鉴定显示,插入的Rz832序列大小约为57bp,与预期结果相同,经测序证实Rz832序列正确。转染pLXSN-Rz832的肝星状细胞(hepaticstellatecells,HSCs)细胞周期蛋白D1mRNA的表达受到明显抑制,仅为对照组的42.22%(t=-193.443,P<0.01),结果表明:Rz832能够在体外特异性切割细胞周期蛋白D1mRNA、并在HSC-T6细胞内有效抑制细胞周期蛋白D1基因的表达。     

Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type 1.

The catalytic domain of a hammerhead ribozyme was incorporated into a 413 nucleotides long antisense RNA directed against the 5'-leader/gag region of the human immunodeficiency virus type 1 (HIV-1) (pos. +222 to +634). The resulting catalytic antisense RNA was shown to cleave its target RNA in vitro specifically at physiological ion strength and temperature. We compared the antiviral effectiveness of this catalytic antisense RNA with that of the corresponding unmodified antisense RNA and with a mutated catalytic antisense RNA, which did not cleave the substrate RNA in vitro. Each of these RNAs was co-transfected into human SW480 cells together with infectious complete proviral HIV-1 DNA, followed by analysis of HIV-1 replication. The presence of the catalytically active domain resulted in 4 to 7 fold stronger inhibition of HIV-1 replication as compared to the parental antisense RNA and the inactive mutant. Kinetic and structural studies performed in vitro indicated that the ability for double strand formation was not changed in catalytic antisense RNA versus parental antisense RNA. Together, these data suggest that the ability to cleave target RNA is a crucial prerequisite for the observed increase of inhibition of the replication of HIV-1.     

Characterization in vitro and in vivo of hammerhead ribozymes directed against murine tumor necrosis factoralpha.

A hammerhead ribozyme directed against murine TNFalpha (mTNFalpha) mRNA has been constructed. In vitro studies showed that this ribozyme was released from the parent molecule by flanking cis-acting hammerhead and hairpin ribozymes. This same anti-mTNFalpha ribozyme specifically cleaved both synthetically derived substrate RNA and mTNFalpha mRNA within a pool of total cellular RNA. Endogenous delivery of this anti-mTNFalpha ribozyme via the self-cleaving cassette reduced mTNFalpha mRNA and protein levels in lipopolysaccharide (LPS)-stimulated, stably transfected murine macrophage RAW 264.7 cells. When complexed to liposomes and exogenously delivered to mouse peritoneal macrophages, the same ribozyme, with and without the cis-acting ribozymes, reduced mTNFalpha protein levels. However, an irrelevant ribozyme delivered in an identical fashion was also effective at reducing mTNFalpha protein levels. These data suggest that anti-mTNFalpha ribozymes can be constructed which efficiently cleave mTNFalpha mRNA, but irrelevant RNA/liposome complexes also effectively limit TNFalpha mRNA expression and can mimic functional ribozyme activity under in vitro conditions.     

Ribozyme inhibition of alphavirus replication

A model system to examine the expression and antiviral activity of trans-acting ribozymes in mammalian cells has been developed and evaluated. Hairpin ribozymes were engineered to cleave a specific site, identified by a combinatorial activity-based selection method, within genomic and subgenomic RNA species of Sindbis virus. Transiently transfected cells expressed moderate levels of ribozyme (approximately 50,000 molecules/cell) with predominant nuclear localization and a short half-life (23 min). Stable cell lines expressed ribozymes at modest levels (approximately 2,000 molecules/cell). Ribozyme-mediated RNA cleavage activity was detected in cell extracts. Clonal cell lines were challenged with recombinant Sindbis virus, and viral replication was examined using plaque formation and green fluorescent protein assays. Significant inhibition of viral replication was observed in cells expressing the active antiviral ribozyme, and lower levels of inhibition in control cells expressing inactive or irrelevant ribozymes. These findings are consistent with a model in which inhibition of viral replication occurs via ribozyme cleavage of viral RNAs, suggesting that ribozymes may represent useful antiviral agents.     

Inhibition of telomerase in tumor cells by ribozyme targeting telomerase RNA component

Telomerase plays an important role in cell proliferation and carcinogenesis and is believed to be a good target for anti-cancer drugs. Elimination of template function of telomerase RNA may repress the telomerase activity. A hammer-headed ribozyme (telomerase ribozyme, te-loRZ) directed against the RNA component of human telomerase (hTR) was designed and synthesized. TeloRZ showed a specific cleavage activity against the hTR. The cleavage efficacy reached 60%. A eukaryotic expression plasmid containing teloRZ gene was inducted into HeLa cells by lipofectamine, the telomerase activity in HeLa cells expressing teloRZ decreased to one eighth of that in the control cells. The doubling time increased significantly and the apoptosis ratio was elevated with increasing population doublings (PDS). After 19-20 PDS 95% cells were apoptotic. To further investigate the effect of teloRZ on tumor growth, the eukaryotic expression plasmid containing teloRZ was injected into transplanted tumor of nude mouse. The teloRZ e